These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33388444)

  • 1. Subdermal Contraceptive Implant Insertion Trends and Retention in Adolescents.
    Tyson N; Lopez M; Merchant M; Postlethwaite D
    J Pediatr Adolesc Gynecol; 2021 Jun; 34(3):348-354. PubMed ID: 33388444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal Trends in the Uptake and Continuation of the Etonogestrel Implant in a Large Private Practice Setting.
    Howard DL; Ford A; Ceballos S; Volker KW
    J Womens Health (Larchmt); 2018 Feb; 27(2):191-195. PubMed ID: 28976797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six- and twelve-month documented removal rates among women electing postpartum inpatient compared to delayed or interval contraceptive implant insertions after Medicaid payment reform.
    Crockett AH; Pickell LB; Heberlein EC; Billings DL; Mills B
    Contraception; 2017 Jan; 95(1):71-76. PubMed ID: 27400823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attendance of an Initial Follow-up Visit after Long-Acting Reversible Contraception Insertion and Method Continuation Among Adolescents and Young Adults: A Retrospective Study.
    Bryson AE; Cabral HJ; Coles MS
    J Pediatr Adolesc Gynecol; 2021 Aug; 34(4):525-529. PubMed ID: 33486086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adolescent Long-Acting Reversible Contraceptive Use, Same-Day Insertions, and Pregnancies Following a Quality Initiative.
    Bruce KH; Merchant MA; Kaskowitz AP; Mickelsen RS; Lau JS
    J Adolesc Health; 2023 Nov; 73(5):946-952. PubMed ID: 37436353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between BMI and continuity of etonogestrel (ENG)-releasing implant.
    Mohr-Sasson A; Dalal L; Bhalwal A
    Int J Gynaecol Obstet; 2024 Oct; 167(1):254-258. PubMed ID: 38712353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
    Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
    Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users.
    Peterson AM; Brown A; Savage A; Dempsey A
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):475-479. PubMed ID: 31545110
    [No Abstract]   [Full Text] [Related]  

  • 11. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting.
    Tocce K; Sheeder J; Python J; Teal SB
    J Pediatr Adolesc Gynecol; 2012 Feb; 25(1):59-63. PubMed ID: 22051792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.
    Ireland LD; Goyal V; Raker CA; Murray A; Allen RH
    Contraception; 2014 Sep; 90(3):253-8. PubMed ID: 24973904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
    López Del Cerro E; Serrano Diana C; Castillo Cañadas AM; González Mirasol E; García Santos F; Gómez García MT; González de Merlo G
    J Obstet Gynaecol; 2018 Oct; 38(7):979-984. PubMed ID: 29553853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-abortion contraception with etonogestrel subdermal implant.
    Barros Pereira I; Carvalho RM; Graça LM
    Eur J Obstet Gynecol Reprod Biol; 2015 Feb; 185():33-5. PubMed ID: 25522115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life of women using the etonogestrel long-acting reversible contraceptive implant after abortion for unplanned pregnancy.
    Caruso S; Vitale SG; Fava V; Pasqua SD; Rapisarda AMC; Cianci S
    Eur J Contracept Reprod Health Care; 2020 Aug; 25(4):251-258. PubMed ID: 32436733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long acting reversible contraception in adolescents with cardiovascular conditions.
    Amies Oelschlager AM; Micks EA; Debiec KE; Nizamic T; Mantrala MD; Prager SW
    J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):353-5. PubMed ID: 25256877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation and continuation of long-acting reversible contraception in the United States military healthcare system.
    Chiles DP; Roberts TA; Klein DA
    Am J Obstet Gynecol; 2016 Sep; 215(3):328.e1-9. PubMed ID: 27005514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
    Berlan E; Mizraji K; Bonny AE
    Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
    Hubacher D; Spector H; Monteith C; Chen PL; Hart C
    Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.